Icon (NASDAQ:ICLR) Director Eugene Pacelli Mccague Sells 3,255 Shares of Stock

Icon Plc (NASDAQ:ICLR) Director Eugene Mccague sold 3,255 shares of the stock in a transaction dated Thursday, September 17th. The shares were sold at an average price of $175.00, for a total transaction of $569,625.00. Following the completion of the sale, the director owned 3,811 shares of the company’s stock, valued at approximately $666,925. The trade was a 46.07% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Eugene Pacelli Mccague also recently made the following trade(s):

• On Tuesday, August 11th, Eugene Mccague sold 841 shares of Icon stock. The stock was sold at an average price of $164.29, for a total value of $138,167.89.

Icon Price Performance

Shares of ICLR stock opened at $164.11 on Friday. Icon Plc has a 12 month low of $66.57 and a 12 month high of $203.91. The company has a market capitalization of $12.57 billion, a P/E ratio of 38.52, a P/E/G ratio of 7.85 and a beta of 1.20. The stock has a 50 day moving average of $167.19 and a two-hundred day moving average of $140.18. The company has a current ratio of 0.95, a quick ratio of 0.95 and a debt-to-equity ratio of 0.23.

Icon (NASDAQ:ICLR) last issued its earnings results on Thursday, July 30th. The medical research company reported $2.56 EPS for the quarter, beating analysts’ consensus estimates of $2.55 by $0.01. Icon had a return on equity of 8.02% and a net margin of 3.99%.The business had revenue of $2.06 billion during the quarter, compared to analyst estimates of $2 billion. During the same period in the prior year, the company posted $3.26 earnings per share. Icon’s revenue was up 2.3% on a year-over-year basis. As a group, equities analysts expect that Icon Plc will post 9.56 EPS for the current year.

Analyst Ratings Changes

ICLR has been the topic of a number of analyst reports. DA Davidson set a $164.00 price target on Icon in a research report on Monday, June 1st. William Blair raised Icon to a “strong-buy” rating in a report on Thursday, July 30th. Weiss Ratings restated a “sell (d)” rating on shares of Icon in a research report on Wednesday, August 26th. Citigroup dropped their price target on Icon from $180.00 to $175.00 and set a “neutral” rating for the company in a report on Friday. Finally, Leerink Partners set a $145.00 price objective on Icon in a research report on Thursday, May 28th. One research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, seven have issued a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat.com, Icon presently has a consensus rating of “Hold” and a consensus price target of $170.07.

Institutional Investors Weigh In On Icon

A number of institutional investors and hedge funds have recently modified their holdings of ICLR. Capital World Investors raised its position in shares of Icon by 555.2% during the 4th quarter. Capital World Investors now owns 1,496,479 shares of the medical research company’s stock valued at $272,688,000 after acquiring an additional 1,268,095 shares during the last quarter. Lyrical Asset Management LP bought a new position in shares of Icon in the 4th quarter worth $176,382,000. Norges Bank acquired a new stake in shares of Icon during the fourth quarter worth $160,073,000. Maple Rock Capital Partners Inc. grew its stake in shares of Icon by 257.8% during the second quarter. Maple Rock Capital Partners Inc. now owns 1,199,600 shares of the medical research company’s stock worth $208,383,000 after purchasing an additional 864,300 shares during the period. Finally, Van Lanschot Kempen Investment Management N.V. bought a new stake in Icon in the fourth quarter valued at about $135,489,000. 95.61% of the stock is owned by institutional investors.

Icon Company Profile

ICON plc is a contract research and development organization that provides services to pharmaceutical, biotechnology, medical device and government clients. The company helps sponsors plan, manage and execute clinical development programs, supporting the progression of new medicines and healthcare products from early research through regulatory approval and commercialization.

Its services include clinical trial design and management, clinical data management, biostatistics, pharmacovigilance, regulatory consulting, medical affairs, laboratory services and real-world evidence.